This study tests a new eye treatment called KPI-012 for people with **persistent corneal epithelial defect** (PCED), a condition where the surface of the eye doesn't heal properly. About 90 people will join this study in the U.S. Participants will be randomly chosen to receive either the new treatment or a placebo (a substance with no therapeutic effect) for 8 weeks. Researchers will compare how well the eye heals in each group. The whole study lasts around 34 weeks, from start to finish.
- **Participation Length**: The study takes about 34 weeks.
- **Visits Needed**: Multiple visits to the study center are required.
- **Treatment and Risks**: Participants will receive either KPI-012 or a placebo, with risks including possible side effects from the treatment.